LAS VEGAS, NY / ACCESSWIRE / June 27, 2016 / A few biotech companies could be set to heat up now that the summer is officially here.

Endonovo Therapeutics, Inc. (ENDV) is currently at the forefront of a revolutionary approach to treating injuries and illnesses called bioelectronic medicine. This rapidly emerging segment of medicine seeks to harness the electrical impulses cells and nerves use to control inflammation and healing in tissues and organs. What really sets Endonovo apart from its competitors is ENDV non-invasive device does not require implantation into patients. ENDV’s technology uses rapidly changing magnetic fields to deliver electrical stimulation deep into tissues, an effect known as Faraday coupling, which is the same fundamental operating principle of transformers and many types of electrical motors and solenoids. Endonovo uses these platform technologies to both directly reduce inflammation via a non-invasive medical device and grow and enhance stem cells for cell therapies and tissue engineering.

Recently, the company received a price target of $1.15 from See Thru Equity research. With the company currently priced at 25 cents a share, reaching the target price would represent a 360% price gain.

The report cites ENDV’s “potentially disruptive Immunotronics™ and Cytotronics™ platforms.”

as a major driver behind their valuation. The report also cited a few major upcoming events that could drive their target even higher:

• 2H2016E Immunotronics Preclinical study for liver disease
• 1H2017E Immunotronics IDE application submitted to FDA
• 1H2017E Cytotronics Orphan Drug Designation for Graft versus Host Disease
• 1H2017E Estimated $2mn $5mn financing; possibly in conjunction with a listing on a national exchange
• 2H2017E Immunotronics Human clinical trials begin

About Immunotronics

ENDV’s Immunotronics platform is being developed to control inflammation in vital organs in order to treat and prevent organ failure and other inflammatory conditions, such acute liver injury. ENDV’s initial concentration focuses on treating inflammation in the liver and augmenting its regeneration using its non-invasive medical device.

BCC Research’s most recent report on the global market for liver disease therapeutics, found approximately $24.5 billion was spent in 2014 treating liver diseases and expects the investment in liver disease to grow to $33.8 billion by 2019, a CAGR of 6.7 percent.

About Cytotronics

ENDV’s other large opportunity lies in their Cytotronics platform, which uses electrical stimulation to produce more potent stem cells. ENDV is initially focused on treating Graft Versus Host Disease “GVHD” and expanding the use and effectiveness of cord blood stem cells. GVHD, occurs when cells from a transplanted organ attack the recipient’s body. GVHD primarily occurs following a stem cell, bone marrow or tissue transplant.

Global spending treating the disease was about $300 million in 2013 and is expected to grow at a CAGR of 12.8 percent to $545 million in 2023 according to research from Future Markets Insight. This is another major opportunity for Endonovo.

Tetralogic Pharmaceuticals Corp. (TLOG) had a huge day Monday, up 62% on over 5 million shares; this stock is receiving serious interest and you should start paying attention too.

Lpath, Inc. (LPTN) shares are skyrocketing, up over 58% in afternoon trading after the company announced that it has been awarded a $1.45 million two­year grant by the Defense Medical Research and Development Program (DMRDP), which is an agency of the U.S. Department of Defense (DOD).

Fate Therapeutics, Inc. (FATE) another next generation stem cell company like ENDV, has surged by over 20% after the company said the U.S. Food and Drug Administration (FDA) has granted Fast Track status to ProTmune, its drug for the reduction of the incidence and severity of acute graft­versus­host disease (GvHD). The San Diego, California based biopharmaceutical company also announced that Phase 1/2 clinical trial of ProTmune in adult subjects with hematologic malignancies is open for patient enrollment. In a statement, Chris Storgard, M.D., Chief Medical Officer of Fate Therapeutics, said that the company is looking forward to work with FDA to “rapidly advance” its innovative immunotherapy through the clinical development and regulatory processes.

Minerva Neurosciences (NERV) surged ahead of their presentation Tuesday at the JMP Securities Life Sciences Conference in New York.

A biopharmaceutical player that’s starting to trend within range of triggering a big breakout trade is NewLink Genetics (NLNK), which focuses on discovering, developing and commercializing immunotherapeutic products to enhance treatment options for patients with cancer. This stock had been destroyed by the bears over the last six months, with shares down big by 70.7%.

If you take a glance at the chart for NewLink Genetics, you’ll notice that this stock recently formed a double bottom chart pattern, after shares found some buying interest at $9.76 to $9.84 a share. Following that potential bottom, this stock has now started to spike higher off those support levels, and it’s quickly trending within range of triggering a near­term breakout trade above some key overhead resistance levels.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.

SOURCE: ACR Communication, LLC

ReleaseID: 441672

LAS VEGAS, NV / ACCESSWIRE / June 27, 2016 / Propanc Health Group Corporation (PPCH) has just announced significant progress of development activities ahead of the First­In­Man studies for their PRP treatment.

First­In­Man studies are exactly what they sound like, the first studies on human subjects, in some circles it is referred to as Phase 0.

Why is this big?

Because this means PPCH is close to becoming a clinical stage biotechnology company. This is a major milestone on the horizon. There are several markers in between which should make for exciting announcement and could help bring this oversold company back to its 2015 highs.

“Over the last six months, Propanc’s development team has worked extremely hard to progress PRP to a stage where a constructive discussion could be held with the MHRA to define our development pathway,” said James Nathanielsz, Propanc’s Chief Executive Officer. “I am pleased to say we had a successful meeting and are working hard to complete the activities necessary to support a clinical trial application. So far, it appears we are on track to complete this goal early next year and I am delighted with the level of commitment and effort shown by our Development team. As I mentioned previously, we are presently transforming into a clinical stage biopharmaceutical company and I expect more exciting developments to unfold this year as we progress towards first­ in­ man studies for PRP.”

Point is, Propanc is sitting at a bottom, and has a litany of positive announcements ahead potentially. Now would be a great time to buy your tickets for what should be a fun ride up heading into next year’s trials.

Here’s a couple other comeback stocks making waves in the market.

Achaogen, Inc. (AKAO) was recently upgraded to outperform by Wedbush and their analysis looks to be proven right so far.

Mast Therapeutics (MSTX) has recovered this week despite less than stellar Q1 numbers.

ProNAi Therapeutics, Inc. (DNAI) was perhaps the biggest loser from the ASCO meeting. The company announced interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory diffuse large B­cell lymphoma. Results from this mid­stage trial were disappointing and modest efficacy was seen, at best. However, the clinical stage company has worked backup since their struggles.

Immunomedics, Inc. (IMMU) is undergoing a class action lawsuit.

Otonomy, Inc. (OTIC) recently initiated patient enrollment for their Phase 3 Clinical Trial of OTIPRIOTM in patients with Acute Otitis Externa.

Of all of these comeback candidates, PPCH is our favorite.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.

SOURCE: ACR Communication, LLC

ReleaseID: 441669

NEW YORK, NY / ACCESSWIRE / June 27, 2016 / Levi & Korsinsky announces it has commenced an investigation of Luby’s, Inc. (NYSE: LUB) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to: http://zlk.9nl.com/lubys-lub or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 441674

NEW YORK, NY / ACCESSWIRE / June 27, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Skullcandy, Inc. (NASDAQ: SKUL) stock prior to June 23, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Skullcandy, Inc. to Incipio, LLC for $5.75 in cash per Skullcandy share. On June 24, 2016, Skullcandy received an unsolicited proposal from Mill Road Capital, offering to acquire Skullcandy for $6.05 per share.To learn more about the action and your rights, go to: http://zlk.9nl.com/skullcandy-merger or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 441673

VANCOUVER, BC / ACCESSWIRE / June 27, 2016 / Avanti Energy Inc. (TSX-V: AVN) (“Avanti” or the “Company”) is pleased to announce that Avanti Energy Inc.’s Italian subsidiary, CMI Energia SpA (CMI) has completed its environmental impact study for the Colle Santo block in Central Italy, and has now formally submitted the study to the Ministry of Environment for review and approval.

CMI managing director Mark Frascogna, stated, “We are very pleased with the work that our team of professionals from Olimar srl, TEA Ambiente, TEA Sistemi, Ediltop srl, Libra Engineering, and DREAM has now completed. The permit application requires a large and in depth body of work and we are confident that the submission is of the highest quality. We are looking forward to moving our Colle Santo project to project sanction.”

The environmental impact study covers the gas production, pipeline, and gas treatment segments of the development program and is the second and final filing under Italian regulations. The first submission detailing the proposed work program was provided to the Ministry of Economic Development (UNMIG division) on April 18, 2016.

Located in central Italy, the Colle Santo project is the largest undeveloped onshore gas field in Italy. As previously announced, Avanti has identified an extension to the Colle Santo field that has tremendous potential to expand the existing reserves. CMI is operator and, along with its partners, owns a 90-per-cent (net 33.3 per cent) working interest in the project.

For more information regarding the Company please contact Kirk Gamley, corporate communications, at 604-689-7422.

“Karl Kottmeier“
Director

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: Avanti Energy Inc.

ReleaseID: 441671

NEW YORK, NY / ACCESSWIRE / June 27, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Immunomedics, Inc. (“Immunomedics”) (NASDAQ: IMMU) between April 20, 2016 and June 2, 2016.

You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. If you purchased or otherwise acquired Immunomedics securities between April 20, 2016 and June 2, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/immunomedics or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) the Company’s abstract for antibody-drug IMMU-132 submitted to the American Society of Clinical Oncology (“ASCO”) for presentation at the 2016 ASCO Annual Meeting contained previously disclosed results from a mid-stage study; (2) Immunomedics misrepresented to ASCO that the abstract for IMMU-132 contained only updated and previously undisclosed data; (3) the foregoing misrepresentation was a violation of ASCO policy and made the IMMU-132 presentation subject to removal from the 2016 ASCO Annual Meeting schedule; and (4) as a result, Immunomedics’ public statements were materially false and misleading at all relevant times.

If you suffered a loss in Immunomedics you have until August 8, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 441666

NEW YORK, NY / ACCESSWIRE / June 27, 2016 / Bronstein, Gewirtz & Grossman, LLC, notifies investors of a class action against Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ-GM: IMMU). The class action has been filed in the United States District Court, District of New Jersey, on behalf of a class consisting of all persons or entities who purchased Immunomedics common stock between April 20, 2016 and June 2, 2016 inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

Immunomedics is a clinical-stage biopharmaceutical company that researches, develops, manufactures and sells monoclonals and ELISA kits, for use in cancer and autoimmune diagnosis, detection and therapy.

Immunomedics is known for its antibody-drug conjugate sacituzumab govitecan IMMU-132 (“IMMU-132”), currently in Phase II trials for treatment of patients with metastatic triple-negative breast cancer and small-cell and non-small-cell lung cancers.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the abstract for IMMU-132 that Immunomedics submitted to the American Society of Clinical Oncology (“ASCO”) for presentation at the 2016 ASCO Annual Meeting contained outdated results from a mid-stage study; (2) Immunomedics had misrepresented this information to ASCO as if its abstract IMMU-132 only listed updated and previously undisclosed data; (3) the misrepresentation was a violation of ASCO policy and made Immunomedics’ IMMU-132 presentation subject to removal from the 2016 ASCO Annual Meeting schedule; and (4) consequentially, Immunomedics’ public statements were materially false and misleading at all relevant times.

On April 19, 2016, Immunomedics said it would update its results for IMMU-132 treatment for ASCO’s Annual Meeting scheduled in June 2016.

On June 2, 2016, after the market closed, media outlets reported that the American Society of Clinical Oncology (“ASCO”) had removed a scheduled presentation by Immunomedics regarding the Company’s IMMU-132 breast cancer drug from ASCO’s annual meeting. ASCO stated that Immunomedics had misrepresented that the Company’s abstract for IMMU-132 contained updated and previously undisclosed results from a mid-stage study, when in fact the IMMU-132 data that Immunomedics submitted were old and previously seen.

Following this news, Immunomedics stock dropped $0.78, or 14.72%, to close at $4.52 on June 3, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action please visit the firm’s site: http://www.bgandg.com/#!immu/sypgi or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Immunomedics you have until August 8, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441619